|
|
|
|
This review follows a 1 day meeting of the authors in November 2000 and examines current evidence for the use of IVIg in neurological conditions and comments on mechanisms of action, delivery, safety and tolerability, and health economic iss ues. Evidence of efficacy has been classified into levels for healthcare interventions. |
|